Quantcast

Latest Diclofenac Stories

2014-09-12 16:23:36

DUBLIN, Sept. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Diclofenac Industry Report 2014" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The Global Diclofenac Industry Report 2014 is a professional and in-depth study on the current state of the global diclofenac industry . The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The...

2014-09-10 23:02:27

ReportsnReports.com adds “2014 Market Research Report on Global Diclofenac Industry” and “2014 Deep Research Report on Global and China DL-Mandelic Acid Industry” report to its store. Dallas, TX (PRWEB) September 10, 2014 2014 Market Research Report on Global Diclofenac Industry is a professional and in-depth study on the current state of the Diclofenac industry in Global and China. The report provides a basic overview of the industry, including definitions, applications and...

2014-09-08 08:29:52

MISSISSAUGA, ON, Sept. 8, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has reached a full settlement with Mallinckrodt Inc. of Nuvo's claims and Mallinckrodt's counterclaim relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid(®) and Pennsaid 2% in the United States. Under the terms of the settlement agreement, Mallinckrodt will return...

2014-09-05 16:23:02

NEWARK, Calif., Sept. 5, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Judge Kentaji Brown Jackson of the federal district court for the District of Columbia has granted Depomed's motion for summary judgment in the company's lawsuit against the United States Food and Drug Administration seeking an order requiring the FDA to grant Gralise(®) (gabapentin) Orphan Drug exclusivity for the management of postherpetic neuralgia (PHN). The court's ruling requires...

2014-09-04 08:29:46

NEWARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that it has priced its registered offering of $300 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes"). The offering was upsized from the previously announced $230 million aggregate principal amount. The Notes will bear interest at a rate of 2.50% per year, payable semiannually on March 1 and September 1 of each year, beginning on March 1, 2015. Depomed, Inc....

2014-09-02 16:25:38

NEWARK, Calif., Sept. 2, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that it intends to offer, subject to market and other conditions, $230 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the underwriters in the offering a 30-day option to purchase up to an additional $34.5 million aggregate principal amount of the Notes. Morgan Stanley & Co. LLC and RBC Capital Markets, LLC...

2014-08-25 16:27:20

NEWARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Morgan Stanley 2014 Global Healthcare Conference in New York City. The presentation at the Morgan Stanley conference is scheduled for 2:40 pm ET (11:40 am PT) on Wednesday September 10, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast...

2014-08-25 08:27:26

New Indication in Chronic Pain Marks Company's Third FDA Approval in Less Than a Year PHILADELPHIA, Aug. 25, 2014 /PRNewswire/ -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today the United States Food and Drug Administration (FDA) has approved ZORVOLEX® (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain. This marks the second indication...

2014-08-19 12:28:53

NEWARK, Calif., Aug. 19, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation lawsuit against Actavis, Inc. related to Actavis's Abbreviated New Drug Application for generic versions of Depomed's Gralise(®) (gabapentin) tablets for the management of postherpetic neuralgia. Judge Pisano's ruling finds that Actavis infringes all...

2014-08-04 16:26:29

NEWARK, Calif., Aug. 4, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of R. Scott Shively, as Chief Commercial Officer and Senior Vice President. Mr. Shively has extensive commercial leadership experience in sales and marketing of pain and neurology products, for both specialty as well as larger pharmaceutical companies. Mr. Shively served as Executive Vice President and Chief Commercial Officer of Zogenix from November 2012 through August...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related